Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1691-1705
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1691
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1691
Figure 2 Targeted therapies used in systemic treatment of advanced pancreatic cancers.
AKT: Protein kinase B; VEGFR: Vascular epidermal growth factor receptor; ERK: Extracellular signal-related kinase; FGFR: Fibroblast growth factor receptor; GTP: Guanosine triphosphate; MEK: Mitogen-activated protein kinase; mTOR: Mammalian target of rapamycin; NTRK: Neurotrophic tyrosine receptor kinase; PI3K: Phosphoinositide-3-kinase; PKD1: Polycystic kidney disease 1; RAF: Raf proto-oncogene; RAS: RAS proto-oncogene.
- Citation: Leowattana W, Leowattana P, Leowattana T. Systemic treatment for advanced pancreatic cancer. World J Gastrointest Oncol 2023; 15(10): 1691-1705
- URL: https://www.wjgnet.com/1948-5204/full/v15/i10/1691.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i10.1691